Silver Nanoparticles Nanocarriers, Synthesis and Toxic Effect on Cervical Cancer Cell Lines

Rocio Casañas Pimentel, Eduardo San Martín Martínez, Alberto Monroy García, Consuelo Gómez-García, Quetzaliztli G. Alvarado Palacios

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Silver nanoparticles (AgNPs) have been suggested as a potential tool for the anticancer treatment, but their pharmacological effect has not been tested in vivo because of their high reactivity and adverse effects. In this study, we developed AgNPs of 5 ± 2 nm of diameter through the chemical reduction of silver nitrate (AgNO3) with dextrose, employing gelatin as a surfactant agent, and encapsulated them in nanocarriers with a biocompatible surface based on polyethylene glycol through a modification of the emulsion solvent-evaporation technique. AgNPs nanocarriers (AgNPs-NT) showed diameters between 30 nm and 120 nm in dry samples and from 40 nm to 250 nm in aqueous solution. Different doses of free and encapsulated AgNPs were evaluated in vitro on the cervical cancer-derived cell lines HeLa and CaSki, by flow cytometry studies at 24 h, employing propidium iodide (PI) and carboxyfluorescein diacetate succinimidyl ester (CFSE) as reporter molecules. Both free and encapsulated AgNPs were toxic for both cell lines, inducing important decrements on the cell viability compared with cisplatin (PC, 0.250 mM) and the negative control (NCtrl) comprising only the cell culture media, the vehicle of the AgNPs (0.360 mM), and the vehicle of the AgNPs-NT (1.089 mM). In both cases (HeLa and CaSki cells), AgNPs-NT seem to be less effective than free AgNPs, but this AgNPs-NT had a biocompatible surface, adequate size, and high toxicity observed in vitro. © 2013 Springer Science+Business Media New York.
Original languageAmerican English
Pages (from-to)198-207
Number of pages177
JournalBioNanoScience
DOIs
StatePublished - 1 Jun 2013

Fingerprint

Poisons
Silver
Cells
Nanoparticles
Dextrose
Silver Nitrate
Flow cytometry
Propidium
Gelatin
Emulsions
Cell culture
Surface-Active Agents
Cisplatin
Polyethylene glycols
Toxicity
Culture Media
Nitrates
Esters
Evaporation
Surface active agents

Cite this

@article{17cbc3be56d44f139c8c976cb5c0871c,
title = "Silver Nanoparticles Nanocarriers, Synthesis and Toxic Effect on Cervical Cancer Cell Lines",
abstract = "Silver nanoparticles (AgNPs) have been suggested as a potential tool for the anticancer treatment, but their pharmacological effect has not been tested in vivo because of their high reactivity and adverse effects. In this study, we developed AgNPs of 5 ± 2 nm of diameter through the chemical reduction of silver nitrate (AgNO3) with dextrose, employing gelatin as a surfactant agent, and encapsulated them in nanocarriers with a biocompatible surface based on polyethylene glycol through a modification of the emulsion solvent-evaporation technique. AgNPs nanocarriers (AgNPs-NT) showed diameters between 30 nm and 120 nm in dry samples and from 40 nm to 250 nm in aqueous solution. Different doses of free and encapsulated AgNPs were evaluated in vitro on the cervical cancer-derived cell lines HeLa and CaSki, by flow cytometry studies at 24 h, employing propidium iodide (PI) and carboxyfluorescein diacetate succinimidyl ester (CFSE) as reporter molecules. Both free and encapsulated AgNPs were toxic for both cell lines, inducing important decrements on the cell viability compared with cisplatin (PC, 0.250 mM) and the negative control (NCtrl) comprising only the cell culture media, the vehicle of the AgNPs (0.360 mM), and the vehicle of the AgNPs-NT (1.089 mM). In both cases (HeLa and CaSki cells), AgNPs-NT seem to be less effective than free AgNPs, but this AgNPs-NT had a biocompatible surface, adequate size, and high toxicity observed in vitro. {\circledC} 2013 Springer Science+Business Media New York.",
author = "{Casa{\~n}as Pimentel}, Rocio and {San Mart{\'i}n Mart{\'i}nez}, Eduardo and {Monroy Garc{\'i}a}, Alberto and Consuelo G{\'o}mez-Garc{\'i}a and {Alvarado Palacios}, {Quetzaliztli G.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s12668-013-0085-6",
language = "American English",
pages = "198--207",
journal = "BioNanoScience",
issn = "2191-1630",
publisher = "Springer Science + Business Media",

}

Silver Nanoparticles Nanocarriers, Synthesis and Toxic Effect on Cervical Cancer Cell Lines. / Casañas Pimentel, Rocio; San Martín Martínez, Eduardo; Monroy García, Alberto; Gómez-García, Consuelo; Alvarado Palacios, Quetzaliztli G.

In: BioNanoScience, 01.06.2013, p. 198-207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Silver Nanoparticles Nanocarriers, Synthesis and Toxic Effect on Cervical Cancer Cell Lines

AU - Casañas Pimentel, Rocio

AU - San Martín Martínez, Eduardo

AU - Monroy García, Alberto

AU - Gómez-García, Consuelo

AU - Alvarado Palacios, Quetzaliztli G.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Silver nanoparticles (AgNPs) have been suggested as a potential tool for the anticancer treatment, but their pharmacological effect has not been tested in vivo because of their high reactivity and adverse effects. In this study, we developed AgNPs of 5 ± 2 nm of diameter through the chemical reduction of silver nitrate (AgNO3) with dextrose, employing gelatin as a surfactant agent, and encapsulated them in nanocarriers with a biocompatible surface based on polyethylene glycol through a modification of the emulsion solvent-evaporation technique. AgNPs nanocarriers (AgNPs-NT) showed diameters between 30 nm and 120 nm in dry samples and from 40 nm to 250 nm in aqueous solution. Different doses of free and encapsulated AgNPs were evaluated in vitro on the cervical cancer-derived cell lines HeLa and CaSki, by flow cytometry studies at 24 h, employing propidium iodide (PI) and carboxyfluorescein diacetate succinimidyl ester (CFSE) as reporter molecules. Both free and encapsulated AgNPs were toxic for both cell lines, inducing important decrements on the cell viability compared with cisplatin (PC, 0.250 mM) and the negative control (NCtrl) comprising only the cell culture media, the vehicle of the AgNPs (0.360 mM), and the vehicle of the AgNPs-NT (1.089 mM). In both cases (HeLa and CaSki cells), AgNPs-NT seem to be less effective than free AgNPs, but this AgNPs-NT had a biocompatible surface, adequate size, and high toxicity observed in vitro. © 2013 Springer Science+Business Media New York.

AB - Silver nanoparticles (AgNPs) have been suggested as a potential tool for the anticancer treatment, but their pharmacological effect has not been tested in vivo because of their high reactivity and adverse effects. In this study, we developed AgNPs of 5 ± 2 nm of diameter through the chemical reduction of silver nitrate (AgNO3) with dextrose, employing gelatin as a surfactant agent, and encapsulated them in nanocarriers with a biocompatible surface based on polyethylene glycol through a modification of the emulsion solvent-evaporation technique. AgNPs nanocarriers (AgNPs-NT) showed diameters between 30 nm and 120 nm in dry samples and from 40 nm to 250 nm in aqueous solution. Different doses of free and encapsulated AgNPs were evaluated in vitro on the cervical cancer-derived cell lines HeLa and CaSki, by flow cytometry studies at 24 h, employing propidium iodide (PI) and carboxyfluorescein diacetate succinimidyl ester (CFSE) as reporter molecules. Both free and encapsulated AgNPs were toxic for both cell lines, inducing important decrements on the cell viability compared with cisplatin (PC, 0.250 mM) and the negative control (NCtrl) comprising only the cell culture media, the vehicle of the AgNPs (0.360 mM), and the vehicle of the AgNPs-NT (1.089 mM). In both cases (HeLa and CaSki cells), AgNPs-NT seem to be less effective than free AgNPs, but this AgNPs-NT had a biocompatible surface, adequate size, and high toxicity observed in vitro. © 2013 Springer Science+Business Media New York.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878051228&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84878051228&origin=inward

U2 - 10.1007/s12668-013-0085-6

DO - 10.1007/s12668-013-0085-6

M3 - Article

SP - 198

EP - 207

JO - BioNanoScience

JF - BioNanoScience

SN - 2191-1630

ER -